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Introduction
In this study, we link RAP1A and RAP1B to KS and identify the KMT2D-containing ASCOM complex as a major regulator of the MEK/ERK pathway, thus providing insight into the molecular mechanisms underlying KS.
Results
We performed trio whole-exome sequencing in a KS patient negative for mutations in the known KS genes ( Figure 1A and Table 1 ). Filtering for Mendelian violations did not identify any pathogenic de novo variants, and screening for possible recessive alleles did not produce a likely candidate. However, we observed paternal uniparental isodisomy (UPD) for chromosome 1, which was confirmed by microsatellite marker analysis of chromosome 1 (Figure 2A ). Filtering the UPD region for coding alleles with a minor allele frequency (MAF) of less than 1% led to the identification of 12 novel homoallelic variants (Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI80102DS1). The missense variant c.488G>C in RAP1A was located within the region of a 12-Mb duplication of chromosome 1p13.1-p22.1 previously identified in a KS patient (22) and was predicted to alter protein function (PolyPhen-2: http:// genetics.bwh.harvard.edu/pph2/; PROVEAN: http:// provean.jcvi.org/index.php) (Supplemental Figure 1) . Sanger sequencing confirmed the heterozygous carrier status in the father, while the index patient was homozygous, lacking a maternal WT allele ( Figure  1B) . The c.488G>C variant is predicted to change the conserved arginine at position 163, located close to the phosphorylation site at serine 180 (Human Protein Reference Database: http://www.hprd.org/), to threonine ( Figure 1 , C and D, and Supplemental Figure 2A ). We did not find this change in 270 ethnically matched control individuals, nor was it present in any available control data sets such as 1000 Genomes (1KG; http://www.1000genomes.org/), the approximately 13,000 chromosomes in the Exome Variant Server (EVS; http://evs.gs.washington.edu/EVS/), or the approximately 120,000 alleles in the Exome Aggregation Consortium browser (ExAC; http://exac.broadinstitute.org/). Notably, there was no loss-of-function mutation found in RAP1A in any individual in ExAC, suggesting that this gene is under strong negative selection. Neither Sanger sequencing of all RAP1A-coding exons nor quantitative PCR detected another pathogenic mutation or structural variant in 78 additional KMT2D mutation-negative KS patients, suggesting that RAP1A is a rare contributor to KS.
To evaluate the candidacy of RAP1A in our patient, we tested whether the mutation might affect RAP1A activity. We first purified GTP-bound RAP1A (mutant or WT) with RalGDS-RBD beads (23) ; although the overall protein amounts of the mutant protein were not altered appreciably, we observed a reduction of active, GTP-bound RAP1A after stimulation of cells with EGF ( Figure 2B ), suggesting a loss-of-function mechanism. Since expression of target genes has been shown (13) , the downstream pathomechanism of KS has not yet been elucidated.
RAP1A, and the highly related protein RAP1B (95% amino acid identity), belong to the Ras family of small GTPases, regulating various cellular processes such as cell adhesion and migration (14) (15) (16) ; studies in Xenopus and zebrafish have shown that rap1a and rap1b morphants exhibit similar gastrulation defects, highlighting the important role of both proteins in early development (17) . RAP1 is known to exert opposing effects on the MAPK pathway (18) , depending on tissue-and cell-specific context: an activating effect through BRAF (19, 20) and a repressive effect through RAF1 (21) . loss-of-function allele ( Figure 2C and Supplemental Figure 2C ). To assess this effect by objective quantitative measurements, we performed in situ labeling of embryos with a riboprobe cocktail against myoD, pax2, and krox20, and we measured the ratio of the distal ends of the fifth somite (width [W]) versus the length of the notochord (length [L]). Consistent with a CE defect, depletion of rap1 increased the W/L ratio, which can be rescued by human RAP1A WT , but not by RAP1A R163T mRNA ( Figure  2D ). Additionally, to ascertain the specificity of the CE defects, we tested whether deletion of rap1a, rap1b, or both in the same genome would reproduce the rap1 MO phenotypes. We therefore induced deletions in each gene by CAS9/gRNA (25) . In the F0 generation, we observed CE defects in 45% and 20% of embryos for rap1a and rap1b, respectively; combinatorial injection of guide RNAs for both genes induced CE defects in approximately 70% of embryos ( Figure 3A ). Genotyping of 24 double-mutant embryos showed changes for 22 and 21 embryos for rap1a and rap1b, respectively ( Figure 3 , B and C). These data, together with the rescue of the CE defects with WT mRNA, showed that the phenotype is specific to the targeted genes.
Since our data suggest that mutations in RAP1A are likely causative of KS, we speculated that the closely related gene RAP1B might also be involved in the etiopathology of KS. Initial analysis of our KS cohort (n = 78) did not identify likely pathogenic point mutations or structural variants. However, we identified a de novo mutation in RAP1B (c.451A>G; p.Lys151Glu) by trio whole-exome sequencing ( Supplemental Table 1 ) in a patient initially diagnosed with Hadziselimovic syndrome (MIM 612946), a disorder that overlaps clinically with KS. Careful clinical reevaluation revealed that the patient's phenotype fits the KS spectrum (Table 1 , Figure  4A , and Supplemental Table 2 ). The c.451A>G allele ( Figure 4B ) was absent from all databases (1KG, EVS, and ExAC) and was predicted computationally to be deleterious. The conserved lysine 151 ( Figure 4C ) is located close to the GTP-binding site of RAP1B (Supplemental Figure 2B ). We tested the activity of this RAP1B allele using the in vivo CE complementation assay: RAP1B mRNA encoding Glu at position 151 failed to rescue rap1 morphants (Figure 4, D and E) in a manner similar to the RAP1A mutant allele, while expression of the mutant allele in control embryos was indistinguishable from the expression of WT RAP1B mRNA (data not shown), likely excluding a dominant negative effect. Together, these data suggested a model of haploinsufficiency for RAP1B.
To further investigate the relevance of RAP1 signaling to KS, we set out to test whether suppression of the known KS genes KMT2D and KDM6A would phenocopy RAP1 morphants/CRISPR mutants. To this end, we generated MOs against the sole orthologs of KMT2D and KDM6A. Using the same morphometrics as for rap1 morphants, we found that kmt2d and kdm6a morphants exhibited shorter anterior-posterior axis, wider notochord ( Figure 5A) , and significantly increased somitic/notochord W/L ratio (P < 0.01) compared with controls ( Figure 5B ). Although the large size of KMT2D rendered rescue experimentally intractable, we saw efficient suppression of kmt2d by reverse transcriptase-PCR (RT-PCR) ( Figure 5C ), and we reproduced the phenotype with a second, nonoverlapping kmt2d MO ( Figure 5A ). Coinjection of kdm6a MO with human KDM6A WT mRNA rescued CE defects, providing evidence for specificity ( Figure 5A ).
we saw residual basal activity, it is possible that p.Arg163Thr is a hypomorphic allele. We next tested the effect of the RAP1A variant in a zebrafish model. Given the redundancy between rap1a and rap1b during gastrulation, we injected morpholinos (MOs) silencing both rap1a and rap1b and we scored 50 to 100 embryos/injection for convergent-extension (CE) defects (blind to injection cocktail) according to previously established criteria (class I embryos have grossly normal morphology, but are shorter than control-injected embryos at the same somatic age; class II embryos are shorter and thinner than class I embryos and have poorly developed head, eye, and tail structure, with poor somatic definition and symmetry; ref. 24) . We observed CE defects that could be rescued by coinjection of rap1 MO with 0.5 pg of WT human RAP1A mRNA (RAP1A WT ; P < 0.0001). In agreement with our in vitro data, coinjection of rap1 MO with a human RAP1A mRNA encoding p.Arg163Thr (RAP1A R163T ) was significantly worse than WT (P < 0.0001), but indistinguishable from rap1 MO , providing a second line of evidence that p.Arg163Thr is a whether this phenotype was common to the known and the new KS genes, and we sought to explore its mechanistic basis. We therefore examined rap1, kmt2d, and kdm6a morphants at 5 days post fertilization (dpf) and stained their cartilaginous structures
Patients with KS may present with skeletal changes, such as brachydactyly, and defective jaw development, i.e., retrognathia, malocclusion, and/or cleft palate (5) . Aberrant jaw development has been seen previously in CE mutants (26, 27) . We asked of chondrocytes ( Figure 6C ). Whole-cell counts of the CH arches did not reveal any differences between control embryos and rap1 and kmt2d morphants ( Figure 6D ), suggesting that the observed anatomical differences were not caused by changes in overall cell number. We therefore considered arrangement defects, and we counted the number of cells between the boundaries of CH arches. In control CH arches, we found an average of 3 to 4 cells between boundaries ( Figure 6E ). In contrast, CH arches from rap1 and kmt2d morphants contained an average of 5 chondrocytes, a significant difference (P < 0.0001; Figure 6E ). These data indicated that the observed hypognathia might be caused by a perturbation of cell intercalation, a phenotype consistent with defective CE movements (28) . To probe the mechanistic basis of this observation further and to determine whether a rearrangement of the cytoskeleton is involved in cell intercalation (29) , we examined whether rap1 and kmt2d are necessary for the formation of the actomyosin network. Utilizing phalloidin and myosin IIa staining, we found that (a) chondrocytes in the CH arch of rap1 and kmt2d morphants fail to line up in a well-organized "fence-like" configuration; (b)
with Alcian blue. All 3 morphants exhibited similar changes of cartilage layout: a kinked ceratohyal (CH) cartilage and a shortened distance between the Meckel (MK) and CH arches ( Figure  6A and Supplemental Figure 3 , A and B), a phenotype also reproduced in our rap1 Cas9/gRNA mutants (Supplemental Figure 3 , C and D). Measuring the distance between the MK and CH cartilage along the midline showed that depletion of rap1, kmt2d, and kdm6a significantly decreases the distance between the MK and CH arches (P < 0.001; Figure 6B and Supplemental Figure 3B ). Moreover, and in agreement with our earlier data, RAP1A WT but not RAP1A R163T mRNA rescues the jaw phenotype in rap1 morphants ( Figure 6 , A and B). As shown in the ventral view of the jaw layout of 5-dpf embryos ( Figure 6A ), the CH cartilage of rap1 and kmt2d morphants is shorter and wider compared with control embryos, a phenotype unlikely to be secondary to an overall head-size defect, since the dimension measured was along the anterior-posterior axis that was not grossly affected in our embryos. To explore the cellular basis of this phenotype, we dissected CH arches and evaluated the arrangement while actin filaments (F-actin) localized mainly at the membrane area of the control cells; this could not been seen in rap1 and kmt2d morphants; and (c) myosin IIa was distributed asymmetrically (polarized) in control embryos but not in rap1 and kmt2d morphants (Supplemental Figure 4A ). RAP1A R163T patient fibroblasts stained with phalloidin showed equivalent disorganization of the actin cytoskeleton (Supplemental Figure 4B ). We conclude that both the RAP1 and the ASCOM proteins play an important role in actin dynamics and cell intercalation. Since knockdown (KD) of rap1 and the known KS genes produced similar cartilage phenotypes, we wondered whether a direct biochemical relationship existed between RAP1 and KMT2D in vivo. Coinjection of subeffective MO doses (Supplemental Figure 5A ) for rap1 and kmt2d exacerbated the CE defects of embryos compared with those injected by each single MO (P < 0.0001; Figure 7A ), raising the possibility that these 2 genes interact genetically. Moreover, expression of RAP1A WT but not RAP1A R163T mRNA rescued the CE defects of kmt2d morphants (P < 0.001; Figure 7B ) as well as the subsequent effects caused by kmt2d depletion, such as MAPK hyperactivation and cytoskeleton disorganization (Supplemental Figure 5 , B and C), suggesting that RAP1 is downstream of KMT2D. To test whether KMT2D regulates the transcription of the RAP1 genes (RAP1A and RAP1B), we assayed the expression of endogenous rap1a and rap1b in kmt2d morphants. Expression levels of rap1a were indistinguishable from those of control embryos. However, we saw a significant downregulation of rap1b in kmt2d-depleted embryos (P < 0.001; Figure 7C ).
This result argued for a direct relationship between KMT2D and RAP1B. To explore this possibility further, we performed ChIP in KMT2D haploinsufficient patient fibroblasts. We found that these cells exhibited reduced H3K4 trimethylation at the RAP1B promoter and, consequently, a reduced expression of human RAP1B (Figure 7 , D and E). The RBBP5 protein, a core protein of the ASCOM complex, was found to bind to the RAP1B promoter region in WT human fibroblasts (Supplemental Figure 6 , A and B), supporting further the direct regulation of RAP1B expression by KMT2D.
RAP1 plays opposing roles in the MAPK pathway: as an activator through BRAF and as a repressor through RAF1 ( Figure 8A and refs. [19] [20] [21] . Given the known role of RAP1 in the MAPK pathway, we wondered whether the genetic defects in KS converge on a common pathophysiology governed by altered MEK/ ERK signaling. We therefore investigated whether biochemical MEK/ERK defects can be observed in models of KS in vitro and in vivo. First, we examined fibroblasts from the index RAP1A R163T patient. We found a reduced level of phospho-MEK1/2 (pMEK1/2), suggesting that, in this cell type, the p.Arg163Thr allele attenuates the ability of RAP1A to activate MEK/ERK signaling ( Figure 8B Figure  7D ). Finally, in addition to reduced active MEK1/2 ( Figure 8B ), RAP1A R163T patient fibroblasts showed a reduction in BRAF phosphorylation, without apparent changes in total BRAF ( Figure 9A ). Both of these alterations could be rescued by WT RAP1A transfection ( Figure 9 , B and C). Consistent with these data, KD of BRAF in cells derived from a patient with the KMT2D nonsense mutation p.Arg5027* enhanced the reduction of pMEK, while overexpression of BRAF increased pMEK levels ( Figure 9 , D and E). Taken together, these data support the notion that RAP1A acts mainly via activation of BRAF in this cellular context. Coimmunoprecipitation experiments revealed no alterations in the interaction of RAP1A WT -GFP or RAP1A R163T -GFP with BRAF after EGF stimulation, indicating that the reduced RAP1-mediated BRAF activation in the RAP1A R163T fibroblasts is not a result of impaired interaction, but probably of failed RAP1 activation ( Figure 9F ). Next, we tested whether the observed pathway defects were also relevant in the in vivo phenotypes of rap1 morphants. Western blotting of midsomitic whole-embryo lysates showed that suppression of rap1 during development leads to increased MEK/ERK signaling, which, similarly to in earlier experiments, could not be rescued upon expression of the p.Arg163Thr allele and was phenocopied by suppression of kmt2d ( Figure 10A ). We hypothesized that, in this developmental context, rap1 is likely to act through inhibition of raf1 (21) and consequently, that raf1 hyperactivation would underlie the observed MEK hyperactivation in the rap1 morphant. If this were true, suppression of raf1 should rescue the rap1 morphant phenotype, whereas expression of BRAF mRNA should have no effect. Masked analysis of approximately 100 embryos coinjected with MO against rap1 and either raf1 MO or BRAF mRNA confirmed this hypothesis: raf1 MO rescued CE (P < 0.0001), while expression of WT BRAF mRNA did not alter the rap1 morphant phenotype or the hypognathia of the rap1 morphants (P < 0.0001; Figure 10 , B and C, and Supplemental Figure 8 , A-C). In addition, depletion of raf1 also reduced MEK hyperactivation in the rap1 morphant (Supplemental Figure 8D) .
As a result of these findings, we hypothesized that pharmacological treatment of zebrafish embryos with a MAPK agonist should phenocopy the rap1 morphant phenotype in WT embryos and worsen the phenotype of the rap1 morphants, while treatment of rap1 MO embryos with a MAPK antagonist should have an ameliorating effect. We found both predictions to be true. First, injection of embryos with 4 μM of the MAPK agonist PAF-C16 (30) induced CE and hypognathia defects in approximately 50% of embryos and enhanced the CE phenotype of rap1 morphants when rap1 MO was coinjected with PAF-C16 ( Figure 10 , D and E). Second, although injection of the MEK inhibitor PD184161 (31) in WT embryos also induced mild CE defects (Supplemental Figure 8E) , it attenuated both the CE defects (P < 0.0001; Figure 11A ) and the structural cartilage defect in rap1 morphants, as indicated by the significantly improved distance between the MK and CH arches (P < 0.001; Figure 11B ). Finally, since we have shown that altered MEK/ERK signaling is also relevant in KMT2D-mediated KS, possibly through the transcriptional regulation of RAP1B expression, we speculated that treatment with the MEK inhibitor PD184161 would also ameliorate the phenotypes observed in kmt2d morphants. Indeed, we observed significant improvement of the CE and jaw defects in kmt2d morphants (Figure 11 , C and D).
Discussion
Here, we have shown that RAP1A and RAP1B contribute to the pathogenesis of KS, the former through the conversion of a heterozygous allele to functional homozygosity by UPD and the latter through a heterozygous germline mutation and as a downstream Activating MAPK pathway mutations, including mutations in both BRAF and RAF1 as well as MEK1 and MEK2, have been found in several RASopathies, including Noonan, Costello, LEOPARD, and cardiofaciocutaneous (CFC) syndromes (35) (36) (37) , all of which have features that overlap with KS. For example, short stature, developmental delay, skeletal abnormalities, and congenital heart defects can be found in all of these disorders (Supplemental Table  2 ). Our study suggests that the pathophysiology of KS overlaps with that of the RASopathies. The subcellular defects observed in our study might contribute not only to the skeletal defects in KS, but also to other KS-associated phenotypes, such as heart and renal defects, both of which have been observed in CE mutants with defective cell intercalation (38, 39) and especially in rap1 morphants (40) . Our data also demonstrate that the genetic defects in KS can have opposite effects, either activating or silencing, on the MAPK pathway, depending on whether the RAP1 proteins operate through BRAF or RAF1. These effects, which are likely dependent on cell type and developmental context, might underlie different aspects of the disease. RAP1A loss-mediated hyperactivation of the MAPK pathway impairs the inflammatory response (41) . Alter-target of KMT2D (and presumably of KDM6A). Although the involvement of RAP1A and RAP1B is rare, our morphometric and biochemical studies point to a convergence of defects in KS on the MAPK pathway; not only do zebrafish morphants for all 4 KS genes manifest the same anatomical defects, but the biochemical results of in vivo and in vitro analyses are also consistent with this hypothesis. The anatomical and cellular findings suggest further that RAP1 and KMT2D coordinate cell intercalation through the function of polarized actin and myosin IIa. Since skeletal changes are often observed in KS patients, as in the present cases (Table 1) , these observations are likely relevant to human pathology.
Chromatin-modifying enzymes such as KMT2D play a fundamental role in cell differentiation and homeostasis during embryonic development and in adult organisms (32) (33) (34) . The influence of these proteins, and the respective multiprotein complexes such as ASCOM, on chromatin state and gene activation are well analyzed. However, less is known about their downstream effects. Our results shed a light on the cellular mechanisms affected by ASCOM action and dysfunction and link the function of these proteins to the MAPK pathway as one of the major signaling cascades affected in KS. as the MEK/ERK signaling pathway play an important role in various cancer types (46, 47) , the functional link between these 2 systems might help to further promote the understanding of cancer pathogenesis and therapy.
Methods
Patients. We studied 2 nonconsanguineous families of Turkish origin who each had 1 affected child. EDTA blood samples were collected from the 2 affected boys and their parents, and DNA was extracted from peripheral blood lymphocytes by standard extraction procedures. Fibroblasts were obtained from skin biopsies of patients according to standard protocols. Exome sequencing (trio analysis): RAP1A. Genomic DNA libraries from each of the trio samples were prepared from 3 μg of starting DNA using the Agilent Sure Select Human All Exon 50 Mb Kit (baits are based on the complete annotation of coding regions from the GEN-CODE project; Agilent Technologies). The resulting fragment libraries, comprising overlapping fragments covering 50 Mb of the exome, were sequenced from both ends (100 bp paired-end sequencing) using Illumina HiSeq 2000 running version 2 chemistry (Illumina). An average of 36 million reads was generated for each sample. Sequence reads were mapped to the reference genome (hg19: GRCh37: Feb2009) using the Burrows-Wheeler Aligner (BWA) (version 0.5.9). The alignment was refined to ensure reads were correctly mapped around ations in chemotaxis of lymphoid and myeloid cells have been observed in Rap1a-KO mice (42) . These observations are in line with the increased susceptibility to upper airway tract and middle ear infections as well as different levels of immune deficiencies or autoimmune challenges described in KS patients. Likewise, the MAPK pathway is critical in mediating a host of neurodevelopmental processes through the regulation of gene expression, including neurogenesis and neuronal plasticity (43) . We speculate that alterations in these MAPK-driven neuronal processes might underlie impaired cognitive development, which could be accessible to postnatal pharmacological treatment in patients with KS (44) . Pharmacological MEK/ERK inhibition at neonatal stages was shown to rescue brain anomalies in an animal model of an Nf1-related RASopathy (45) . In our study, we were able to rescue the craniofacial defects in zebrafish models of KS by suppressing raf1. Thus, treatment with MAPK-altering drugs might prove beneficial to KS patients. FDA-approved RAF kinase inhibitors such as sorafenib and vemurafenib are presently licensed to treat renal cell carcinoma and melanoma, respectively. Further studies are needed to investigate whether these or novel therapeutic compounds influencing the MAPK pathway could be a practicable therapeutic option for the treatment of several postnatal aspects of the disease, such as cognition, growth, and immune function. Moreover, since the methyltransferases of the KMT2 group as well The resulting variants were filtered to exclude variants present in dbSNP135, EVS, 1KG, and our in-house database and variants that were not predicted to affect protein sequence or exon splicing. For de novo analysis, all variant loci in the patient's data set were compared with the parental data sets. Only variants covered in all 3 samples and present in less than 5% of the reads in the parental data sets were considered. Table 3 ) for 29 microsatellite markers were retrieved from the UCSC genome browser and were purchased from Metabion (Planegg) and IDT DNA. Marker analysis was performed according to standard protocols by PCR amplification and GeneScan on an ABI PRISM 3100 Genetic Analyzer using the GeneScan 500 ROX standard and GeneScan software from Applied Biosystems (Life Technologies).
Microsatellite marker analysis. Primer sequences (Supplemental
Sanger sequencing. PCR and sequencing primers (Supplemental Table 3 ) were retrieved from the UCSC genome browser and purchased from IDT DNA. Sanger sequencing was performed according to standard protocols using the BigDye terminator version 1.1, and carried out on a 3730 sequencer by Applied Biosystems (Life Technologies) at the Cologne Center for Genomics. All coding exons of RAP1A were sequenced in 78 patients with KS negative for KMT2D mutations and in 115 patients with Noonan syndrome without mutations in the known RASopathy genes.
insertions and deletions using the Genome Analysis Toolkit (GATK) IndelRealigner (version 1.0.5974). Duplicate reads were marked using Picard (version 1.41) to avoid calling genotypes based on overrepresented library molecules. Base quality scores were then recalibrated using the GATK covariance recalibration tool. An average of 81% of the target exome was covered to 20×, and the mean target coverage in these regions was 64 reads in depth for all samples. SNPs and indels were called using the GATK Unified Genotyper and cross-referenced against known variants from dbSNP132 (http://www.ncbi.nlm.nih. gov/projects/SNP/) and 1KG. A total of 375,937 variations from the reference genome were called after filtering the data according to the GATK Best Practice Variant Detection guidelines (v2). Novel variants in the child were identified using vcftools (v1.0.4a), and the trio was analyzed for violations in Mendelian inheritance using the GATK Select Variants tool. 5,499 novel variants were called in the child, and 595 Mendelian violations were identified. For this analysis, only variants with a coverage greater than 20× were included.
Exome sequencing (trio analysis): RAP1B. Exonic and adjacent intronic regions were enriched from genomic DNA of each patient and his parents using the 50 Mb SureSelect XT Human All Exon Enrichment kit (Agilent Technologies), and sequencing was performed with a HiSeq2000 sequencer from Illumina (Illumina). Alignment against the GRCh37 human reference was performed with the BWA (version 0.6.2), PCR duplicates marking with Picard (version 1.84), indel taken. Cells were lysed with ice-cold lysis buffer (150 mM NaCl, 1 mM EDTA, 1% NP40, 20 mM Tris-HCl, 0.25% SDS, 1 mM Na 3 VO 4 , 10 mM NaF, 0.01 mM Na 2 MO 4 ) and treated with benzonase nuclease (Novagen, Merck KGaA). The total protein concentration was determined by using the BCA Protein Assay Kit (Thermo Fisher Scientific), and 10 μg of whole cell lysate per sample was subjected to reducing 4% to 12% SDS-PAGE (Invitrogen, Life Technologies) and transferred to a nitrocellulose membrane by immunoblotting. Immunoblots were blocked in 5% milk powder in TBS containing 0.1% Tween 20 and probed with pBRAF (sc-28006-R; Santa Cruz Biotechnology Inc.), BRAF (F-3, sc-55522; Santa Cruz Biotechnology Inc.), pMEK1/2 (41G9, catalog 9154; catalog 9121; Cell Signaling), MEK1/2 (L38C12, catalog 4694; Cell Signaling), pERK1/2 (catalog 9101; Cell Signaling) or pERK (E-4, sc-7383; Santa Cruz Biotechnology Inc.), total ERK1 (K-23, sc-94; Santa Cruz Biotechnology Inc.) or ERK2 (610103; BD), and total RAP1A/RAP1B (26B4, no. 2399, respectively; Cell Signaling). pERK antibodies detect endogenous levels of p44 and p42 MAP kinases (ERK1 and ERK2) at Thr202 and Tyr204 of ERK1 and Thr185 and Tyr187 of ERK2. The ERK1 antibody detects total ERK1 p44 and, to a lesser extent, ERK2 p42. The ERK2 antibody exclusively detects endogenous levels of p42 MAP kinase (ERK2). Equal protein amounts were confirmed by β-actin (A 5316; Sigma-Aldrich) detection. Peroxidase-conjugated secondary antibodies (goat anti-mouse: sc-2005, goat-anti-rabbit: sc-2004) were purchased from Santa Cruz Biotechnology Inc., and blots were developed using an enhanced chemiluminescence system, Super Signal West Pico Chemi-Cell lines and cultures. Patient fibroblasts were derived from skin biopsies of the index patient (RAP1A p.Arg163Thr) and a patient with a KMT2D truncating mutation (p.Arg5027*). Control fibroblasts were obtained from skin biopsy of a healthy individual. MEFs were isolated from Kmt2d-KO (Kmt2d -/-) mouse embryos generated in the Genomics Institute, Bio-Innovationszentrum. Primary human skin fibroblasts and MEFs derived from mice were maintained at 37°C in a 5% CO 2 atmosphere in DMEM medium (Gibco; Life Technologies) supplemented with 10% FBS and antibiotics and subcultured at a 1:2 to 1:5 ratio. LCLs were obtained by EBV-mediated transformation of peripheral blood lymphocytes (according to standard methods) from blood samples of 3 patients with different KMT2D mutations (p.Arg5214Cys, p.Try4982*, and p.Pro4632Hisfs*8, respectively). LCLs were maintained in RPMI medium (Gibco; Life Technologies) supplemented with 10% FBS and subcultured at a 1:2 to 1:4 ratio.
Western blot analysis in human fibroblasts. Patient and control fibroblasts were seeded on 10-cm dishes and maintained in serum-free medium (DMEM containing 0.1% FBS) for 48 hours at 37°C. MEFs were seeded on 10-cm dishes and maintained in serum-free medium for 16 hours at 37°C. At a confluence of 70% to 80%, cells were stimulated with 25 ng/ml recombinant human PDGF-BB (R&D Systems) for the indicated times. For rescue experiments in RAP1A R163T patient fibroblasts, we transfected cells with RAP1A WT -pEGFP-N1 using Lipofectamin (Life Technologies) according to the manufacturer's instructions. For Western blot analysis of unstimulated LCLs, 2.5 × 10 6 cells per cell line were for an additional 48 hours. After a total of 72 hours, RNA was directly isolated for RT-PCR analysis (Quantitect primer assay from QIAGEN for BRAF, RAF1, actin) or cells were treated with 25 ng/ml PDGF for 15 minutes and total cell lysates were subjected to Western blot analysis. For BRAF overexpression, 1 × 10 5 KMT2D R5027 * fibroblasts per transfection sample were seeded in 6-well plates 1 day prior to transfection. BRAF overexpression was performed by transfection of pCS2-BRAF. 500 ng DNA was mixed with 3.6 μl FuGENE HD Transfection Reagent (Promega) in a total of 200 μl Opti-MEM according to the manufacturer's instructions and added onto the cells with 1.8 ml fresh DMEM. After 24 hours, cells were lysed and total lysates were subjected to Western blot analysis. Immunoblots were blocked in 5% milk powder in TBS containing 0.1% Tween 20 and probed with BRAF (F-3, sc-55522, Santa Cruz Biotechnology Inc.), pRAF1 (56A6, catalog 9427, Cell Signaling), pMEK1/2 (41G9, catalog 9154, Cell Signaling), and MEK1/2 (L38C12, catalog 4694, Cell Signaling).
Active Rap1 pull-down assay. Detection of active RAP1A was performed using the Active RAP1 Pull-Down and Detection Kit (Thermo luminescent Substrate (Thermo Fisher Scientific), followed by exposure on an autoradiographic film (GE Healthcare).
BRAF knockdown and overexpression in human primary fibroblasts. For BRAF knockdown, 1.5 × 10 5 KMT2D R5027 * fibroblasts per transfection sample were seeded on a 6-cm dish 1 day prior to transfection. BRAF knockdown was performed by siRNA transfection. BRAF and nontargeting AllStars Negative Control siRNA serving as mock control were purchased from QIAGEN. 20 μM siRNA stock was diluted to a final concentration of 1 μM. 220 μl of the 1 μM siRNA dilution was mixed with 220 μl Opti-MEM (Life Technologies), and 4.4 μl DharmaFECT 1 (Thermo Fisher Scientific) was mixed with 435.6 μl Opti-MEM; both mixtures were incubated separately for 5 minutes at room temperature (RT), mixed, and again incubated for 20 minutes at RT. Medium was removed from cells, and 3.5 ml DMEM medium containing 10% FCS and no antibiotics was added. Then the siRNA mixture (final concentration of 50 nM) was added onto the cells. After 24 hours, RNA was directly isolated for RT-PCR analysis or cells were treated as before by serum starvation in medium containing 0.1% FCS Precleared lysates were incubated overnight with 2 μg of the immunoprecipitation (IP) antibody H3K4me3 (ab8580, Abcam) at 4°C with rotation. An additional sample without antibody served as a negative control for quantitative PCR. To collect the antibody-histone-DNA complex, 60 μl of protein A agarose/salmon sperm DNA (50% slurry) was incubated for 1.5 hours at 4°C with rotation. DNA was recovered by phenol/chloroform extraction and ethanol precipitation. The quantitative PCR for RAP1B promoter H3K4 trimethylation was based on amplification of H3K4 trimethylated RAP1B promoter regions in relation to an internal reference promoter region of the HOX7A gene (KMT2Dindependent H3K4 trimethylation) using the QuantiFast SYBR Green PCR Kit (QIAGEN). A total of 4 different primer pairs for 2 different promoter regions of the RAP1B gene and 1 primer pair for a promoter region of HOX7A were designed (methylation sites of RAP1B and HOX7A promoters were previously published, ref. 48) . Primer sequences are presented in Supplemental Table 3 . Realtime PCR was conducted 2 times for each primer pair and DNA sample. Each reaction had 20 μl volume containing 10 μl of 2× QuantiFast SYBR Green PCR Master Mix, 250 nM of the primers, and 5 ng of recovered DNA after ChIP procedure. Thermal cycling was performed for 10 minutes at 95°C and then 40 cycles for 15 seconds at 95°C and for 1 minute at 60°C, followed by a final dissociation stage. The comparative method of relative quantification (2 ΔΔCt ) was used to calculate the relative H3K4me3 level of the RAP1B promoter in patient fibroblasts (normalized to HOX7A) in comparison with control fibroblasts. Results are given as mean ± SD of all 4 primer pairs for patient and control fibroblasts. The IP sample without antibody incubation served as a negative control.
To assay binding of the ASCOM complex at the described H3K4 regions of the RAP1B promoter, primary fibroblasts of a healthy control individual were seeded on 10-cm dishes. ChIP was performed based on the manufacturer's instructions (ChIP Assay Kit, Millipore) with the described changes of the protocol. Precleared lysates were incubated overnight with a dilution of 1:50 of the IP antibody RBBP5 (D3I6P, catalog 13171, Cell Signaling) at 4°C with rotation. An additional sample without antibody served as a negative control for nonquantitative PCR analysis.
Real-time RT-PCR in patient fibroblasts. Total RNA from primary fibroblasts of the patient (KMT2D R5027 *) and a healthy control individual was purified using the RNeasy Mini Kit (QIAGEN). For homogenization of cell lysates, QIAshredder spin columns were used (QIAGEN). Real-time RT-PCR for RAP1B expression analysis was performed using the Power SYBR Green RNA-to-C T 1-Step Kit (Applied Biosystems, Life Technologies). QuantiTect Primer Assays for RAP1B and ACTB RNA as an internal control were purchased from QIAGEN. Each reaction had 20 μl volume containing 10 μl of 2× Power SYBR Green RT-PCR Mix, 0.15 μl RT Enzyme Mix, 2 μl of QuantiTect primer and 25 ng RNA as template. Thermal cycling was performed for 30 minutes at 48°C (reverse transcription step), for 10 minutes at 95°C, and then 40 cycles for 15 seconds at 94°C, and for 30 seconds at 60°C and 35 seconds at 72°C, followed by a final dissociation stage. Real-time RT-PCR was con-Fisher Scientific) according to the manufacturer's instructions. In brief, HEK293T cells were plated in 10-cm dishes 24 hours prior to transfection. Transient transfections were performed with FuGene-HD (Roche) according to the manufacturer's instructions with the expression constructs for GFP-tagged WT human RAP1A and the p.Arg163Thr mutant. One day after transfection, cells were starved in serum-free medium for 24 hours, stimulated with 100 ng/ml recombinant human EGF (R&D Systems) for 5 minutes, and lysed. The total protein concentration was determined using the BCA Protein Assay Kit (Thermo Fisher Scientific), and 200 μg of whole cell lysate per sample was subjected to active RAP1A pull-down.
ChIP assay and quantitative PCR. To quantify RAP1B promoter H3K4 trimethylation, primary fibroblasts of the patient (KMT2D R5027 *) and a healthy control individual were seeded on 10-cm dishes. ChIP was performed based on the manufacturer's instructions (ChIP Assay Kit, Millipore) with the following changes: histones were crosslinked to DNA with a final concentration of 1% formaldehyde in fresh culture medium for 10 minutes at RT. The formaldehyde reaction was quenched by adding glycine to 125 mM for 4 minutes at RT. To shear DNA to lengths between 200 and 1000 bp, lysates were sonicated at 4°C for 16 cycles (30 s ON, 30 s OFF, high power; BioRuptor, Diagenod). Real-time PCR in zebrafish embryos. Total RNA from 10-to 12-somite stage embryos was extracted with TRIzol (Invitrogen, Life Technologies) following the manufacturer's protocol. cDNA was synthesized from 1 μg of total RNA using SuperScript III (Invitrogen). To investigate rap1a and rap1b expression of kmt2d morphants, real-time PCR was performed with Power SYBR Green PCR Master Mix (Applied Biosystems, Life Technologies) on a 7900HT (Applied Biosystems). To obtain the absolute concentration of raf1 and braf expression, serial dilutions of the PCR products of raf1 and braf were used as standards in real-time PCR. Real-time data were collected and analyzed with a Sequence Detection System software package version 2.3 (Applied Biosystems). Primer sequences are presented in Supplemental Table 3 .
Western blot analysis of zebrafish embryos. 10-to 15-dpf embryos were lysed in RIPA buffer (50 mM Tris [pH 7.5], 1% NP-40, 0.1% SDS, 50 mM NaCl, 0.5% Na deoxycholate, 1 mM NaF). After electrophoresis and transferring, the blots were incubated with antibodies as indicated in the figures (pMEK1/2: 1:1000; MEK1/2: 1:3000; Rap1: 1:1000; actin: 1:3000) at 4°C overnight. The images of Western blot were taken by Chemidoc (Bio-Rad) and quantified by Quantity One software (Bio-Rad).
Accession numbers. The following gene reference sequences can be found at http://www.ncbi.nlm.nih.gov/nuccore: RAP1A, NM_001010935.2; RAP1B, NM_015646.5; KMT2D, MLL2; NM_003482.3; KDM6A, NM_021140.3.
Statistics. All results are expressed as the mean ± SD or SEM. All data were analyzed using a 2-tailed Student's t test or the χ 2 test. P < 0.05 was considered statistically significant.
Study approval. We obtained written informed consent from all patients and probands for participation in this study. We obtained written informed consent from the index families for publication of photographs. The study was performed according to the Declaration of Helsinki protocols and was approved by the Ethics Committee of the University of Cologne. The zebrafish experiments were approved by the Ethics Board of Duke University.
